These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 1488020)

  • 1. Evaluation of the genotoxic spectrum of cisplatin for Candida albicans.
    Sarachek A; Henderson L; Wilkens WE
    Microbios; 1992; 72(292-293):183-201. PubMed ID: 1488020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic destabilization of Candida albicans by hydroxyurea.
    Sarachek A; Henderson LA; Eddy KB
    Microbios; 1991; 65(262):39-61. PubMed ID: 2014007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinagenicity of caffeine for Candida albicans.
    Sarachek A; Henderson LA
    Mycopathologia; 1990 May; 110(2):63-76. PubMed ID: 2195351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of responses of Candida albicans to cisplatin by membrane damaging antimycotic agents.
    Sarachek A; Henderson LA
    Mycoses; 1991; 34(3-4):177-82. PubMed ID: 1749398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of cisplatin and two novel palladium complexes on Candida albicans.
    Moussa NM; Ghannoum MA; Whittaker PA; el-Ezaby MS; Quraman S
    Microbios; 1990; 62(252-253):165-78. PubMed ID: 2195302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variations for susceptibilities to ultraviolet induced cellular inactivation and gene segregation among protoplast fusion hybrids of Candida albicans.
    Sarachek A; Henderson LA
    Cytobios; 1988; 55(222-223):171-84. PubMed ID: 3075166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphological and growth altering effects of Cisplatin in C. albicans using fluorescence microscopy.
    Kesavan C; Raghunathan M; Ganesan N
    Ann Clin Microbiol Antimicrob; 2005 Apr; 4():7. PubMed ID: 15850483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated lactoferrin's ability to inhibit Candida growth and block yeast adhesion to the vaginal epithelial monolayer.
    Naidu AS; Chen J; Martinez C; Tulpinski J; Pal BK; Fowler RS
    J Reprod Med; 2004 Nov; 49(11):859-66. PubMed ID: 15603095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining Candida albicans stationary phase by cellular and DNA replication, gene expression and regulation.
    Uppuluri P; Chaffin WL
    Mol Microbiol; 2007 Jun; 64(6):1572-86. PubMed ID: 17555439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
    Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of oxidative stress tolerance resulted in reduced ability to undergo morphologic transitions and decreased pathogenicity in a t-butylhydroperoxide-tolerant mutant of Candida albicans.
    Fekete A; Emri T; Gyetvai A; Gazdag Z; Pesti M; Varga Z; Balla J; Cserháti C; Emody L; Gergely L; Pócsi I
    FEMS Yeast Res; 2007 Sep; 7(6):834-47. PubMed ID: 17498215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent advances in the biology of Candida].
    Odds FC
    Ann Biol Clin (Paris); 1987; 45(5):553-7. PubMed ID: 3322117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candida albicans MTLalpha tup1Delta mutants can reversibly switch to mating-competent, filamentous growth forms.
    Park YN; Morschhäuser J
    Mol Microbiol; 2005 Dec; 58(5):1288-302. PubMed ID: 16313617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity.
    Plooy AC; van Dijk M; Lohman PH
    Cancer Res; 1984 May; 44(5):2043-51. PubMed ID: 6538808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
    Knox RJ; Friedlos F; Lydall DA; Roberts JJ
    Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inter- and intra-species crosses between Candida albicans and Candida guilliermondii.
    Suzuki T; Rogers AL; Magee PT
    Yeast; 1986 Mar; 2(1):53-8. PubMed ID: 3334695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candida albicans switch phenotypes display differential levels of fitness.
    Vargas K; Srikantha R; Holke A; Sifri T; Morris R; Joly S
    Med Sci Monit; 2004 Jul; 10(7):BR198-206. PubMed ID: 15232493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
    Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
    Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic methods and commercial systems for the discrimination between C. albicans and C. dubliniensis.
    Campanha NH; Neppelenbroek KH; Spolidorio DM; Spolidorio LC; Pavarina AC
    Oral Dis; 2005 Nov; 11(6):392-8. PubMed ID: 16269032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic variation in C. albicans.
    Wickes BL; Petter R
    Curr Top Med Mycol; 1996 Dec; 7(1):71-86. PubMed ID: 9504060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.